RecruitingNot ApplicableNCT05890781
Engineering Immune Organoids to Study Pediatric Cancer
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment
108 participants
Start Date
May 12, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Eligibility
Max Age: 25 Years
Inclusion Criteria10
- Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
- Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
- Brain tumors
- Renal tumors
- Neuroblastoma
- Sarcomas
- Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
- Affiliated to a social security system or beneficiary of the same.
- Adult patient or parents/guardians incapable/incapable of giving its/their consent
- Patients deprived of their liberty by a judicial or administrative decision
Interventions
PROCEDURESkin biopsy
Skin biopsy
PROCEDUREFresh tumor sample
Fresh tumor sample
BIOLOGICALBlood sample
Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
PROCEDUREHealthy tissue from the tumor
Healthy tissue from the tumor site whenever possible
PROCEDURESpinal cerebrospinal fluid (SCF)
Spinal cerebrospinal fluid (SCF) whenever possible
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05890781
Related Trials
The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies
NCT062294831 location
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296175 locations
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
NCT040334972 locations
Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment
NCT063527101 location
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCT010056541 location